Clinical Trial Detail

NCT ID NCT02036502
Title A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

multiple myeloma

Therapies

Dexamethasone

Lenalidomide + Pembrolizumab

Age Groups: adult

No variant requirements are available.